Status:
WITHDRAWN
Isoquercetin in Sickle Cell Anemia
Lead Sponsor:
Jeffrey Zwicker, MD
Collaborating Sponsors:
Quercegen Pharmaceuticals
Conditions:
Sickle Cell Disease
Sickle Cell-Beta0-Thalassemia
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
This research study is being done to assess the safety and effectiveness of isoquercetin to reduce levels of soluble P-Selectin in patients with sickle cell disease. Isoquercetin is a naturally occurr...
Detailed Description
This is a single-arm phase 2 study in adults with Sickle Cell Disease (SCD) to assess the effect of oral isoquercetin on biomarkers of endothelial and platelet activation, inflammation and ongoing blo...
Eligibility Criteria
Inclusion
- Eligible subjects require an established diagnosis of sickle cell disease/homozygous hemoglobin S (SCD-SS) or sickle cell disease hemoglobin β0-thalassemia (SCD-Sβ0-thal).
- Patients on other therapy including hydroxyurea will be included.
- Age 18-50 years.
- Participants must have preserved organ and marrow function as defined below:
- leukocytes ≥2,000/mcL
- platelets ≥75,000/mcL
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
- Estimated creatinine clearance ≥45 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
- Subjects with no evidence of worsening over the last 4 weeks (e.g. any acute complication of SCD including but not limited to VOC, acute chest syndrome and stroke, that required unscheduled medical attention or intervention) as determined by the investigator will be included.
- Patients on anticoagulation therapy will be excluded.
- The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of isoquercetin administration.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Please ensure exclusion criteria are clearly worded to describe participants who will not be eligible.
- Participants may not be concurrently receiving any other study agents.
- Subjects with no evidence of worsening over the last 1 month (e.g. any acute complication of SCD including but not limited to VOC, acute chest syndrome and stroke, that required unscheduled medical attention or intervention) as determined by the investigator will be included.
- Familial bleeding diathesis.
- Known diagnosis of disseminated intravascular coagulation.
- Currently receiving anticoagulant therapy.
- Currently using daily use of aspirin (\>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to isoquercetin.
- Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness/social situations that would limit study compliance.
- Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin. These potential risks may also apply to other agents used in this study.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04474626
Start Date
December 1 2020
End Date
December 31 2024
Last Update
January 11 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.